Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to 12 new employees. The awards, approved by the Compensation Committee of the company's Board of Directors on January 2, 2025, consist of non-qualified share options to purchase a total of 67,300 ordinary shares.
The options were granted under Bicycle's 2024 Inducement Plan with an exercise price of $14.00 per share, matching the company's closing price on December 31, 2024. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over 36 months, contingent on continued employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2024 Inducement Plan terms and conditions.
Bicycle Therapeutics (NASDAQ: BCYC) ha annunciato l'assegnazione di premi di incentivazione a 12 nuovi dipendenti. I premi, approvati dal Comitato per la Compensazione del Consiglio di Amministrazione dell'azienda il 2 gennaio 2025, consistono in opzioni su azioni non qualificate per l'acquisto di un totale di 67.300 azioni ordinarie.
Le opzioni sono state assegnate nell'ambito del Piano di Incentivazione del 2024 di Bicycle, con un prezzo di esercizio di $14,00 per azione, corrispondente al prezzo di chiusura dell'azienda del 31 dicembre 2024. Le opzioni matureranno nell'arco di quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente per 36 mesi, a condizione di continuare l'impiego. Questi premi sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4) e sono soggetti ai termini e alle condizioni del Piano di Incentivazione del 2024 dell'azienda.
Bicycle Therapeutics (NASDAQ: BCYC) ha anunciado la concesión de premios de incentivo a 12 nuevos empleados. Los premios, aprobados por el Comité de Compensación de la Junta Directiva de la empresa el 2 de enero de 2025, consisten en opciones de acciones no calificadas para adquirir un total de 67,300 acciones ordinarias.
Las opciones se concedieron bajo el Plan de Incentivo 2024 de Bicycle con un precio de ejercicio de $14.00 por acción, que coincide con el precio de cierre de la empresa del 31 de diciembre de 2024. Las opciones se consolidarán a lo largo de cuatro años, con el 25% consolidándose después de un año y el resto mensual durante 36 meses, condicionado a la continuidad del empleo. Estos premios cumplen con la Regla de Cotización de Nasdaq 5635(c)(4) y están sujetos a los términos y condiciones del Plan de Incentivo 2024 de la empresa.
바이시클 테라퓨틱스 (NASDAQ: BCYC)가 12명의 새로운 직원에게 유인 보상 수여를 발표했습니다. 이 보상은 2025년 1월 2일 회사 이사회의 보상위원회에서 승인되었으며, 67,300주의 보통주를 구매할 수 있는 비상장 주식 옵션으로 구성됩니다.
옵션은 바이시클의 2024년 유인 계획에 따라 부여되었으며, 주당 $14.00의 행사 가격이 설정되어 있습니다. 이는 2024년 12월 31일 회사의 종가와 일치합니다. 이 옵션은 4년에 걸쳐 베스팅되며, 첫 해 후 25%가 베스팅되고 나머지는 36개월 동안 매달 베스팅됩니다. 이는 지속적인 고용을 조건으로 합니다. 이 보상은 나스닥 상장 규정 5635(c)(4)에 부합하며, 회사의 2024년 유인 계획의 조건과 규정에 따릅니다.
Bicycle Therapeutics (NASDAQ: BCYC) a annoncé l'octroi de primes d'incitation à 12 nouveaux employés. Les primes, approuvées par le Comité de Rémunération du Conseil d'Administration de l'entreprise le 2 janvier 2025, consistent en des options d'achat d'actions non qualifiées pour un total de 67 300 actions ordinaires.
Les options ont été accordées dans le cadre du Plan d'Incitation 2024 de Bicycle avec un prix d'exercice de 14,00 $ par action, correspondant au prix de clôture de l'entreprise du 31 décembre 2024. Les options seront acquises sur quatre ans, avec 25 % acquises après un an et le reste s'acquérant mensuellement pendant 36 mois, sous réserve d'une poursuite de l'emploi. Ces attributions sont conformes à la Règle de Cotation Nasdaq 5635(c)(4) et sont soumises aux termes et conditions du Plan d'Incitation 2024 de l'entreprise.
Bicycle Therapeutics (NASDAQ: BCYC) hat die Gewährung von Anreizprämien an 12 neue Mitarbeiter bekannt gegeben. Die Prämien, die am 2. Januar 2025 vom Vergütungsausschuss des Unternehmens genehmigt wurden, bestehen aus nicht qualifizierten Aktienoptionsrechten zum Kauf von insgesamt 67.300 Stammaktien.
Die Optionen wurden im Rahmen des Anreizplans 2024 von Bicycle gewährt, mit einem Ausübungspreis von 14,00 $ pro Aktie, der dem Schlusskurs des Unternehmens am 31. Dezember 2024 entspricht. Die Optionen werden über four Jahre hinweg gültig, wobei 25 % nach einem Jahr und der Rest monatlich über 36 Monate fällig wird, vorausgesetzt, das Beschäftigungsverhältnis besteht weiterhin. Diese Zuwendungen entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und unterliegen den Bedingungen und Bestimmungen des Anreizplans 2024 des Unternehmens.
- Employee retention and attraction strategy implemented through stock options
- Structured vesting schedule promotes long-term employee commitment
- Potential future dilution of existing shareholders through option exercises
- Additional share-based compensation expense impact on financial statements
Each option has an exercise price equal to
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250103712019/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
stephanie.yao@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
How many shares were granted in BCYC's January 2024 inducement awards?
What is the exercise price for BCYC's January 2024 inducement stock options?
What is the vesting schedule for BCYC's 2024 inducement stock options?
How many new employees received BCYC stock options in January 2024?
Under which plan were BCYC's January 2024 inducement awards granted?
